Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis
Main finding · RAResult — go to the resultAdjusted hazard ratio 0.484 95% CI 0.270–0.867Authors' conclusion
Denosumab use reduces the risk of RA in patients with osteoporosis.
Study context
- Population
- Patients with osteoporosis with or without pathological fracture, hospital-based population in Taiwan, 2011–2023, excluding previous rheumatoid arthritis (RA)
- Participants
- 17,065 osteoporosis patients
- Exposure
- Osteoporosis medication users vs non-osteoporosis medication users
- Osteoporosis medication usersn = 7,180
- Non-osteoporosis medication usersn = 9,605reference
- Outcome
- Risk of RA
Methodological detailshospital-based population
- Hospital-based population
Main finding
RA
Adjusted hazard ratio
0.484
95% CI 0.270–0.867
P < 0.05
Osteoporosis medication usersvs Non-osteoporosis medication users
aHR 0.484 (95% CI 0.270–0.867); P < 0.05
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| RA risk, ever use of bisphosphonatesBisphosphonatesvs Non-osteoporosis medication users | 0.405 (0.173–0.951) | P < 0.05 | |
| RA risk, ever use of denosumabDenosumabvs Non-osteoporosis medication users | 0.394 (0.192–0.809) | P < 0.05 | |
| RA risk, denosumab onlyDenosumab onlyvs Non-osteoporosis medication users | 0.32 (0.12–0.83) | P < 0.05 | |
| RA risk, denosumab only, female patients (subgroup)Denosumab onlyvs Non-osteoporosis medication users | 0.26 (0.09–0.74) | P < 0.05 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
- RA risk, ever use of bisphosphonates: n=2069
- RA risk, ever use of denosumab: n=4510
- RA risk, denosumab only: n=2938
RA risk, raloxifene or teriparatide
- Patients taking raloxifene or teriparatide did not have a significantly reduced risk of RA
Original publication
Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis. Clin Exp Rheumatol. Published 25 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →